World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
81
Citations
26143
World Ranking
16556
National Ranking
189

Overview

Mikko Niemi is affiliated with the University of Helsinki in Finland. Their research primarily focuses on medicine, with a particular emphasis on cardiology and cardiovascular medicine, oncology, pharmacology, surgery, and molecular biology. The scope of their work covers key topics such as drug transport and resistance mechanisms, pharmacogenetics and drug metabolism, atrial fibrillation management and outcomes, lipoproteins and cardiovascular health, inflammatory mediators and NSAID effects, antiplatelet therapy and cardiovascular diseases, and pharmacological effects and toxicity studies.

Their recent publications include the following papers:

  • The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms, 2022, Clinical Pharmacology & Therapeutics
  • Vegan diet in young children remodels metabolism and challenges the statuses of essential nutrients, 2021, EMBO Molecular Medicine
  • Comparative Hepatic and Intestinal Efflux Transport of Statins, 2021, Drug Metabolism and Disposition
  • Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users, 2021, Clinical Pharmacology & Therapeutics
  • A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics, 2022, British Journal of Clinical Pharmacology

Frequent collaborators include the following coauthors:

  • Mikko Neuvonen (40 publications)
  • Janne T. Backman (29 publications)
  • Mika Lehto (23 publications)
  • Aleksi Tornio (19 publications)
  • Olli Halminen (18 publications)

Most commonly, Mikko Niemi has published in the following venues:

  • Clinical Pharmacology & Therapeutics (15 publications)
  • European Journal of Pharmaceutical Sciences (8 publications)
  • Basic & Clinical Pharmacology & Toxicology (8 publications)
  • Drug Metabolism and Disposition (4 publications)
  • Clinical and Translational Science (4 publications)

Their research intersects several main fields of study, particularly with a significant number of publications in medicine (179). The subfields being notably represented with numerous contributions include cardiology and cardiovascular medicine (38 publications) and oncology (35 publications), along with pharmacology (32 publications), surgery (22 publications), and molecular biology (13 publications).

Best Publications

  • Membrane transporters in drug development.

    Kathleen M. Giacomini;Shiew Mei Huang;Donald J. Tweedie;Leslie Z. Benet

  • Impact of OATP transporters on pharmacokinetics

    Annikka Kalliokoski;Mikko Niemi

  • Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

    Pertti J. Neuvonen;Mikko Niemi;Janne T. Backman

  • Pharmacokinetic interactions with rifampicin : clinical relevance.

    Mikko Niemi;Janne T. Backman;Martin F. Fromm;Pertti J. Neuvonen

  • Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

    Mikko Niemi;Marja K. Pasanen;Pertti J. Neuvonen

  • SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.

    Marja K. Pasanen;Mikko Neuvonen;Pertti J. Neuvonen;Mikko Niemi

  • High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).

    Mikko Niemi;Elke Schaeffeler;Thomas Lang;Martin F Fromm

  • Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

    Marja K Pasanen;Hanna Fredrikson;Pertti J Neuvonen;Mikko Niemi

  • The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update

    L B Ramsey;S G Johnson;S G Johnson;K E Caudle;C E Haidar

  • ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

    Jenni Keskitalo;O Zolk;Martin F Fromm;Kaisa Kurkinen

  • Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.

    Mikko Niemi;Mikko Niemi;Mikko Niemi;Janne T. Backman;Janne T. Backman;Janne T. Backman;Lauri I. Kajosaari;Lauri I. Kajosaari;Lauri I. Kajosaari;Julian B. Leathart;Julian B. Leathart;Julian B. Leathart

  • Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide

    M. Niemi;J. T. Backman;M. Neuvonen;P. J. Neuvonen

  • The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy

    R. A. Wilke;R. A. Wilke;L. B. Ramsey;S. G. Johnson;S. G. Johnson;W. D. Maxwell

  • Transporter Pharmacogenetics and Statin Toxicity

    M Niemi

  • Role of OATP transporters in the disposition of drugs.

    Mikko Niemi

  • SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.

    Mikko Niemi;Marja K. Pasanen;Pertti J. Neuvonen

  • Lipid-lowering response to statins is affected by CYP3A5 polymorphism.

    Kari T Kivistö;Mikko Niemi;Elke Schaeffeler;Kaisu Pitkälä

  • Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin

    Pertti J Neuvonen;Janne T Backman;Mikko Niemi

  • Global analysis of genetic variation in SLCO1B1

    Marja K Pasanen;Pertti J Neuvonen;Mikko Niemi

  • Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1.

    Anne T Nies;Mikko Niemi;Oliver Burk;Stefan Winter

Frequent Co-Authors

Pertti J. Neuvonen
Pertti J. Neuvonen University of Helsinki
Janne T. Backman
Janne T. Backman University of Helsinki
Eija Kalso
Eija Kalso University of Helsinki
Michel Eichelbaum
Michel Eichelbaum University of Tübingen
Martin F. Fromm
Martin F. Fromm University of Erlangen-Nuremberg
Matthias Schwab
Matthias Schwab University of Tübingen
Teun Bousema
Teun Bousema Radboud University
Mikko Vastaranta
Mikko Vastaranta University of Eastern Finland
Ute Hofmann
Ute Hofmann University of Tübingen
Ann K. Daly
Ann K. Daly Newcastle University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens up many alternative pathways and degrees, especially with the rise of flexible online options. Healthcare professionals looking to advance their careers often consider postgraduate programs like the shortest online dnp program, which allows motivated nurses to move quickly into leadership roles while balancing work and study.

Some may prioritize convenience or have unique licensure needs—if so, a dnp program without clinical hours can be a practical choice, offering an online curriculum with fewer on-site requirements. For those just starting in patient care, an accelerated lpn program is ideal, allowing learners to qualify for entry-level nursing roles more quickly.

For career advancement in specialized mental health roles, consider bridging programs such as an msn to pmhnp online, which can prepare registered nurses for opportunities as Psychiatric Mental Health Nurse Practitioners. These online pathways make it easier than ever to upskill and adapt to the evolving US healthcare landscape.

Best Scientists Citing Mikko Niemi

Trending Scientists